Alexander JH, Wojdyla D, Vora AN, et al. - Given less bleeding with apixaban vs vitamin K antagonist (VKA) and with placebo vs aspirin was reported in patients with atrial fibrillation (AF) and a recent acute coronary syndrome (ACS) and/or those receiving percutaneous coronary intervention (PCI) in AUGUSTUS, however, numerically higher number of ischemic events was reported in relation to treatment with placebo, so, researchers evaluated the tradeoff of risk (bleeding) and benefit (ischemic events) over time with apixaban vs VKA and aspirin vs placebo. Findings revealed that apixaban was preferred over VKA among patients with AF and recent ACS and/or PCI receiving a P2Y₁₂ inhibitor. An equal tradeoff between a rise in severe bleeding and decrease in severe ischemic events was found to be resulted from the use of aspirin acutely and for up to 30 days. Following 30 days, a rise in bleeding with no significant decrease in ischemic events was still noted in relation to treatment with aspirin.